J. Martin-Babau

Predicting severe toxicities and mortality in older patients with colorectal cancer: An analysis of 3 clinical trials and 3 prospective cohorts.

Maxime Rémond, Thomas Aparicio, Claudia Martinez‐Tapia, Karine Le Malicot et autres

INTRODUCTION: Patients over 75 years old account for 40% of incident colorectal cancer (CRC) cases. Predicting chemotherapy (CT)-related toxicities is crucial for guiding treatment decisions. This study aimed to identify predictors of severe toxicities (ST) after 3 months of CT in older …

fr (code pays fourni par la source)

Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2–3 trial

Philippe Merle, Philippe Merle, Jean-Frédéric Blanc, Karine Le Malicot et autres

fr (code pays fourni par la source)

2114P Ramucirumab (Ram) +/- paclitaxel (Pacli) as second-line (L2) therapy in older patients (pts) with advanced esophagogastric adenocarcinomas (EGA): The SOCRATE-PRODIGE 55 randomized phase II study

A. Lievre, M.P. Galais, D. López Trabada, A Delattre et autres

fr, lu (code pays fourni par la source)

Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI)

David Tougeron, Laurent Mineur, Aziz Zaanan, Catherine Poisson Ligeza et autres

BACKGROUND: Metastatic esophageal squamous cell carcinoma (mESCC) patients with disease progression after platinum-based first-line chemotherapy (CT) +/- immune checkpoint inhibitors (ICI) may benefit from second-line CT, mostly based on paclitaxel and irinotecan, but no randomized trial has compared these regimens. PATIENTS AND …

fr, us (code pays fourni par la source)

7MO Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) patients (pts) with RAS/BRAF wild-type (WT) tumor status from circulating DNA (cirDNA): Final results of the randomised phase II PANIRINOX-UCGI28 study

Thibault Mazard, François Ghiringhelli, Lananh Nguyen, Christelle de la Fouchardière et autres

fr, be (code pays fourni par la source)

Sizing and concentration analysis of cfDNA using Biabooster technology: Results from a prospective plasma‐based collection of 77 patients with locally advanced unresectable esophageal cancer

A. Modesto, Sophie Gibert, Caroline Delmas, David Tougeron et autres

Locally advanced esophageal carcinoma remains of poor prognosis correlated with tumor stage. Albeit liquid biopsy approach offers promising results to monitor high-risk patients in various solid tumors, the lack of specific mutation in esophageal tumor, limits the detection of circulating tumor DNA …

fr (code pays fourni par la source)

Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study

Hani M. Babiker, Vincent J. Picozzi, Sreenivasa R Chandana, Hao Chunyi et autres

PURPOSE Tumor treating fields (TTFields) use alternating electric fields to disrupt cancer cell proliferation. Feasibility of TTFields therapy with gemcitabine/nab-paclitaxel was previously demonstrated in patients with advanced pancreatic adenocarcinoma. PANOVA-3 was designed to confirm safety and efficacy of TTFields in patients with …

cn, us, es, cz, kr, jp, de, pl, hu, fr, au, be (code pays fourni par la source)

Impact of paclitaxel on pazopanib pharmacokinetics in patients with ovarian cancers from phase II trial TAPAZ

Aurore Carrot, Benoit You, Florence Joly‐Lobbedez, Michel Fabbro et autres

Background: Combining standard chemotherapy with anti-angiogenic agents could improve efficacy in platinum-resistant recurrent ovarian cancer but is associated with increased toxicity, possibly due to pharmacokinetic (PK) interactions. The objective was to evaluate the impact of paclitaxel on pazopanib PK, and the relationship …

Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancer

Jean-David Fumet, Nicolas Roussot, Aurélie Bertaut, Emeric Limagne et autres

Aim: Trifluridine/tipiracil-bevacizumab is a standard of care in metastatic colorectal cancer (mCRC) after chemotherapy failure. We aim to assess the addition of XB2001 (anti-IL-1 alpha monoclonal antibody) plus trifluridine/tipiracil-bevacizumab in mCRC refractory to standard chemotherapy.Methods: This multicenter, randomized, double blind, non-comparative Phase …

fr, us, cu, lu (code pays fourni par la source)

793TiP A phase III, randomized, open-label, multicenter study of sacituzumab tirumotecan (sac-TMT) monotherapy vs treatment of physician’s choice chemotherapy in patients with endometrial cancer who have received prior chemotherapy and immunotherapy: ENGOT-en23/GOG-3095/MK-2870-005

D. Lorusso, Mansoor Raza Mirza, J. Martin-Babau, Alessandra Bologna et autres

it, dk, fr, es, de, ch, cz, cn, jp, ca, kr, br, au, us (code pays fourni par la source)

600TiP A randomized blinded phase II study of ompenaclid (RGX-202-01) vs placebo in combination with FOLFIRI plus bevacizumab (BEV) in patients (pts) with previously treated RAS mutated (RASmt) advanced/metastatic colorectal cancer (mCRC)

M.E. Elez Fernandez, David Páez, J. Jiménez Castro, F. Rivera Herrero et autres

es, fr, be, us (code pays fourni par la source)

1447P Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study

D. Tougeron, L. Mineur, Aziz Zaanan, Mai Kadi et autres

fr (code pays fourni par la source)